Your browser does not support the NLM PubReader view.
Go to this page to see a list of supporting browsers.

References

1. 

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. https://doi.org/10.1056/NEJMoa1411892

2. 

Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy 2012;32:e7-11. https://doi.org/10.1002/PHAR.1014

3. 

Narayana SK, Talab SK, Elrishi MA. Liraglutide-induced acute kidney injury. Pract Diabetes 2012;29:380-2. https://doi.org/10.1002/pdi.1727

4. 

Food and Drug Administration. Prescribing information for Saxenda, 2018 [Internet]. Food and Drug Administration. 2018 [cited 2022 November 20]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206321s007lbl.pdf

5. 

Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013;4:190-201. https://doi.org/10.4239/wjd.v4.i5.190

6. 

Leehey DJ, Rahman MA, Borys E, Picken MM, Clise CE. Acute kidney injury associated with semaglutide. Kidney Med 2021;3:282-5. https://doi.org/10.1016/j.xkme.2020.10.008